Tag Archive | "Merck KGaA"

M&A: Merck KGaA’s EMD Miilipore acquires Biochrom

Tags: , ,


EMD Millipore, a Merck KGaA subsidiary has entered into definitive M&A agreement to acquire Biochrom, a Berlin based cell culture media specialist company.

Read the full story

Top partnering deals so far in 2012

Tags: , , , , , , , , , , , , , , , ,


The first six months of 2012 have been busy for life science dealmakers, with significant partnerships across numerous therapy areas Read the full story

Merck KGaA signs worldwide pharma licensing with PDS Biotechnology for nanotechnology platform

Tags: , , ,


PDS Biotechnology have entered into an exclusive worldwide pharma licensing agreement with Merck KGaA for use of PDS Biotechnology's novel Versamune nanotechnology platform in two of Merck's investigational antigen-specific cancer immunotherapies currently in pre-clinical development.

Read the full story

MDxHealth inks pharma partners deal with Merck KGaA for cancer Dx

Tags: , , , ,


MDxHealth  has inked a development and commercialization pharma partners deal with Merck KGaA, looking to market a companion diagnostic test for one of the drugmaker's cancer treatments.

Read the full story

Merck Serono seals pharma partnering deal with Dr Reddy’s for biosimilars

Tags: , , ,


Dr. Reddy’s Laboratories and Merck Serono, a big pharma company announced a pharma partnering collaboration to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs) Read the full story

Partnering Agreements with Merck KGaA

Tags: , , , , , , ,


This report provides all the information you require to better understand Merck KGaA / Merck Serono and its partnering interests and activities over the past seven years. Read the full story

Merck Serono engages in pharma partnering with Kadimastem

Tags: , ,


Merck Serono, a big pharma company and Kadimastem announced the signing of a five year pharma partnering framework agreement Read the full story

No major pharma deals for Merck KGaA until 2013

Tags: , ,


Germany's Merck KGaA, a big pharma company will refrain from major pharma deals until the end of next year to focus on cost cuts and job reduction, its Chief Executive said on Friday Read the full story

Merck inks global oncology deal with Threshold

Tags: , ,


Threshold have landed a co-development and licensing deal to TH-302, a clinical candidate being developed for soft-tissue sarcoma and pancreatic cancer Read the full story

Threshold Pharmaceuticals and Merck KGaA announce global agreement to co-develop and commercialize phase 3 hypoxia-targeted drug TH-302

Tags: , ,


Threshold Pharmaceuticals announced that a global agreement was signed with Merck KGaA to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.  Read the full story

cabannerad300x150new4gif
rauconbadgejpg
e78banner300x150animgif
cpbannerad300x150new1gif
rauconbadgejpg
e78banner300x150animgif